

### SECTOR UPDATE

## Technology – Malaysia

Capitalising Before Cyclical Upturn; Be Selective

Conditions for sector risk-on are falling into place after the materialisation of de-rating events alongside appealing valuations. Meanwhile, our empirical study on sector cyclicality against the BM Tech Index also suggests that a sector upswing could be on the cards. While earnings vulnerability is still looming, not all segments are gloom and doom. We prefer companies that are still benefitting from structural growth themes. **Maintain OVERWEIGHT.**

### WHAT'S NEW

- Better risk-reward trade-off after a gloomy 2022.** Our contrarian downgrade since Dec 21 saw the Bursa Malaysia Technology Index (BM Tech Index) plunging by as much as -43% in mid-Oct 22, before narrowing to -34% in end-22. Dampeners such as global uncertainty shocks (high inflation, global slowdown, tightening policies, Russia-Ukraine war, escalating US-China tech race) alongside slower growth (base normalisation, demand slowdown, inventory excess) are falling in place, sending valuations down to -0.5SD to -1SD below their five-year mean levels (from +2SD since end-21). Conditions for turning more bullish on the sector are in a constellation especially after rounds of de-rating alongside appealing valuations. Additionally, the trio of Fed hawkishness, stringency of China's zero-COVID restrictions and supply chain disruptions is peaking, setting a base for this cyclical sector to outperform again in 2023.
- Light at the end of tunnel for turning risk-on?** On top of a better risk-reward profile, our empirical research on the sector cyclicality against the BM Tech Index suggests that the index could be on the brink of an upswing again after 12 months of consolidation. According to the overleaf chart, the study on the relationship of BM Tech Index and global semiconductor sales over the past 15 years showed that the bottoming of BM Tech Index happened between the second to seventh month (average of 4.5 months) after the onset of global semiconductor yoy sales contraction, while we are currently on the third month of yoy sales contraction (Oct 22 data). This suggests that investors tend to look ahead of fundamental weaknesses with better visibility and capitalising on the upturning point of long-term structural growth. We believe this cyclical pattern could repeat itself again.
- Earnings vulnerability still looming but not all is gloom and doom.** While global PC and smartphone giants are still reportedly cutting component orders and scaling back expansion to the extent of downsizing (International Data Corporation forecasted -6.5% smartphone shipment growth in 2022 and cut growth to 2.3% in 2023), our channel checks with the local OSAT and equipment makers suggest that orders related to automobile (EV), medical and renewable energy (RE) are still seeing resilient demand. Indeed, the SPE bellwethers shared that >1/3 of orderbook backlog is made up of these sub-segments which are still seeing healthy growth.

### ACTION

- Maintain OVERWEIGHT** with a cherry-picking approach to structural growth themes. While we have previously ascribed a more conservative valuation across all the technology/semiconductor names under our coverage, we are selectively ascribing a higher valuation to stocks with good growth prospects stemming from: a) front-runners of trade diversion, and b) equipment/solution providers for next-generation technologies – ie EV/higher electrification, medical devices and RE. We like companies with strong orderbook backlogs such as Greatech, Pentamaster and Coraza for their unique value propositions, alpha growths and strong demand visibility. We also like VS Industry (VS) for its undemanding valuation vs a better growth profile.

### PEER COMPARISON

Company	Tickers	Rec	Share Price 3 Jan 23 (RM)	Target Price (RM)	Market Cap (RMm)	PE			EV/EBITDA		P/BV 23F (x)	Dividend Yield	
						22F (x)	23F (x)	24F (x)	22F (x)	23F (x)		22F (%)	23F (%)
Technology – Electronic Manufacturing Services (EMS)													
ATA IMS	AIB MK	SELL	0.22	0.29	258.6	62.1	(4.5)	(17.7)	2.9	(6.7)	0.4	15.6	(7.8)
SKP Resources	SKP MK	BUY	1.61	2.00	2,515.4	15.9	14.8	12.2	9.0	9.1	2.8	3.9	4.2
VS Industry	VSI MK	BUY	0.88	1.40	3,377.3	19.5	14.7	12.9	10.5	7.1	1.7	1.9	3.1
Technology – Semiconductors (OSAT: Outsourced Semiconductor Assembly and Test, SPE: Semiconductor Production Equipment)													
Globetronics	GTB MK	BUY	1.15	1.50	769.9	16.3	14.8	13.9	7.3	6.8	2.4	5.0	5.5
Greatech	GREATEC MK	BUY	4.78	6.30	5,988.6	45.6	26.6	21.3	35.7	21.5	7.6	n.a	n.a
Inari Amertron	INRI MK	BUY	2.62	3.10	9,780.0	24.7	24.2	21.3	14.3	14.3	3.8	3.8	3.7
Pentamaster Corp	PENT MK	BUY	4.57	5.20	3,250.7	36.1	30.8	26.9	17.6	15.0	3.3	0.5	0.6
Vitrox Corp	VITRO MK	BUY	7.65	9.22	7,226.6	35.0	29.1	24.1	30.4	25.4	7.2	1.0	1.2

Source: UOB Kay Hian

## OVERWEIGHT (Maintained)

### OSAT: FORWARD PE




\*OSAT: Outsourced Semiconductor Assembly and Test  
Source: UOB Kay Hian

### SPE: FORWARD PE



\*SPE: Semiconductor Production Equipment  
Source: UOB Kay Hian

### GSS GROWTH DOWNCYCLE FOR THE PAST 10 YEARS



Source: Semiconductor Industry Association (SIA), UOB Kay Hian

### ANALYST(S)

**Desmond Chong**

+603 2147 1980

desmondchong@uobkayhian.com

### ESSENTIALS


- Worsening export curbs – A double-edged sword?** Following the escalation of the US-China tech race - with the latest curb being the tighter restrictions on the sale of semiconductor equipment to Chinese companies, global semiconductor stocks (from front-end to back-end) have broadly retreated >10% on concerns of supply chain disruption. While such concerns are warranted (OSAT and SPE players have already been impacted by slower delivery since 4Q21), this could accelerate the US-China trade diversion which would benefit the small-cap star performers ie SFP, Coraza and Cnenergiz. Our ground check suggests that the queries from MNCs on supply chain reconfiguration are still encouraging.
- Local OSAT players' 2022 sales expected to moderate to 9%/5% yoy in 2022/23 respectively.** While higher semiconductor content following the proliferation of EV and autonomous driving is still expected to drive growth (LMC Automotive projecting that light vehicle unit production will increase 6.0% in 2022 and 4.9% in 2023), shipments of smartphones continue to see headwinds from weakening demand owing to geopolitical tensions and ongoing supply chain constraints (International Data Corporation forecasted -9.1% smartphone shipment growth in 2022 and cut growth to 2.3% in 2023). Note that worldwide smartphone shipments declined 9.7% yoy in 3Q22. This marks the fifth consecutive quarter of decline for the smartphone market. Meanwhile, on the local front, smartphone-related OSAT players are guiding for a softer outlook over next two quarters.
- Local equipment makers: Decent growth; orderbook backlog at all-time high.** Although the growth is coming off from a high base, 2022/23 sales growth is still estimated at a decent 8%/24% on the back of the ongoing investment cycle for EV/autonomous driving, medical and RE even after the strong growth of 45% in 2021. This outperforms global benchmarks due to the US-China trade diversion and the entrenchment of manufacturing capabilities. Meanwhile, orderbook backlogs for most of the companies remain elevated at all-time high levels but delivery remains a challenge due to supply chain disruptions. Nonetheless, the delays are merely due to time issues rather than cancellations.
- Local EMS players bouncing back from a lacklustre 2022 on order rechanneling and revival of foreign labour hiring.** While we are cognisant of the general slowdown in light of the weakening consumer demand, we still expect both SKP's and VS' sales to register high-teens growth on a net basis. Note that VS is benefitting following the fallout of its peer from the common customer's business engagement while SKP is still the front-runner for new product commercialisation from its key customer. Meanwhile, on the manpower supply which is the much needed driver to fuel structural growth, our latest channel checks reveal that EMS players have already onboarded 100% of the required workforce while having the capacities ready to take on additional jobs.
- Downside risks include:** a) longer-than-expected inflation, b) deeper recession, c) more hawkish US monetary policies, d) slower-than-expected sales, e) higher-than-expected cost, and f) more disruptions caused by the COVID-19 pandemic.
- For SPE exposure, we like Greatech and Pentamaster** for their solid orderbook backlogs (early-November: RM888m for Greatech; >RM500m for Pentamaster) with >50% exposure to high-margin EV and/or RE alongside their respective unique value propositions (strategic exposure in the renewable energy, medical and EV industries offer better dynamics to weather cyclicality vs peers) alongside their robust growth. We also like CORAZA (BUY, Target: RM1.10) for its respective strategic portfolio exposure, aggressive capacity expansion and growing relevance in major customers' high-margin products. Meanwhile, non-rated Cnenergiz is also benefitting from the border reopening and the acceleration of trade diversion via its exposure to trade winner destinations such as Thailand, Vietnam and Indonesia.
- For EMS, we like VSI** as it offers a better investment proposition than its peers, with exposure to strategic customers alongside being the clear winner of the trade diversion. VSI is benefitting from the fallout of other EMS players following order rechanneling. We expect VSI to register a two-year net profit CAGR of 23% (from FY22-24), notwithstanding the new meaningful contracts pipeline. Current valuation has also been overly conservative in ignoring its valuable China assets and Seeing Machine Limited.

### GLOBAL SEMICONDUCTOR SALES FORECAST

	Amounts in US\$M			Year on Year Growth in %		
	2021	2022	2023	2021	2022	2023
Americas	121,481	142,138	143,278	27.4	17.0	0.6
Europe	47,721	53,774	54,096	27.3	12.6	0.4
Japan	43,871	48,064	45,290	19.8	10.0	0.4
Asia Pacific	342,967	336,151	311,008	26.5	-2.0	-7.5
<b>Total World - \$M</b>	<b>556,040</b>	<b>580,126</b>	<b>556,568</b>	<b>26.2</b>	<b>4.4</b>	<b>-4.1</b>
Discrete Semiconductors	30,337	34,098	35,060	27.4	12.4	2.8
Optoelectronics	43,404	43,777	46,381	7.4	0.9	3.7
Sensors	19,149	22,262	23,086	28.0	16.3	3.7
Integrated Circuits	463,002	479,989	453,041	28.2	3.7	-5.6
Analog	74,106	89,054	90,562	33.1	20.8	1.6
Micro	80,221	76,790	75,273	15.1	-1.8	-4.5
Logic	154,837	177,238	175,191	30.8	14.5	-1.2
Memory	153,839	134,407	111,624	30.9	-12.6	-17.0
<b>Total Products - \$M</b>	<b>556,040</b>	<b>580,126</b>	<b>556,568</b>	<b>26.2</b>	<b>4.4</b>	<b>-4.1</b>


Note: Numbers in the table are rounded to whole millions of dollars, which may cause totals by region and totals by product group to differ slightly.  
Source: World Semiconductor Trade Statistics (WSTS)

### GLOBAL SEMICONDUCTOR SALES (YOY GROWTH)




Source: Bloomberg, SIA, UOB Kay Hian

### MALAYSIA OSAT SALES GROWTH




Source: Bloomberg, UOB Kay Hian

### MALAYSIA EQUIPMENT MAKER SALES GROWTH




Source: Bloomberg, UOB Kay Hian

### GLOBAL SEMICONDUCTOR SALES AND GROWTH




Source: World Semiconductor Trade Statistics

### GLOBAL EQUIPMENT MAKER SALES AND GROWTH




Source: Semiconductor Equipment and Materials International

### MALAYSIA OSAT NET PROFIT AND MARGIN



Source: Bloomberg, UOB Kay Hian

### MALAYSIA EQUIPMENT MAKER NET PROFIT AND MARGIN



Source: Bloomberg, UOB Kay Hian

### TECHNOLOGY DOWNCYCLE PLOT AGAINST BURSA MALAYSIA TECHNOLOGY INDEX



Source: Bloomberg, UOB Kay Hian

## Disclosures/Disclaimers

This report is prepared by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

**This report is prepared for general circulation.** It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of UOBKH. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as UOBKH may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject UOBKH and its connected persons (as defined in the Financial Advisers Act, Chapter 110 of Singapore) to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report ("Information") has been obtained or derived from sources believed by UOBKH to be reliable. However, UOBKH makes no representation as to the accuracy or completeness of such sources or the Information and UOBKH accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information. UOBKH and its connected persons may have issued other reports expressing views different from the Information and all views expressed in all reports of UOBKH and its connected persons are subject to change without notice. UOBKH reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) UOBKH, its connected persons and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) UOBKH, its connected persons and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of UOBKH may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the "Subject Business"); and (4) UOBKH may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

**IMPORTANT DISCLOSURES FOR U.S. PERSONS**

This research report was prepared by UOBKH, a company authorized, as noted above, to engage in securities activities in Singapore. UOBKH is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by UOBKH (whether directly or through its US registered broker dealer affiliate named below) to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). All US persons that receive this document by way of distribution from or which they regard as being from UOBKH by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc ("UOBKHUS"), a registered broker-dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UOBKH.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

### Analyst Certification/Regulation AC

Each research analyst of UOBKH who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKH or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including UOBKH's total revenues, a portion of which are generated from UOBKH's business of dealing in securities.

Reports are distributed in the respective countries by the respective entities and are subject to the additional restrictions listed in the following table.

General	This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to applicable law or regulation.
Hong Kong	This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong Kong and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong Kong in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Indonesia	This report is distributed in Indonesia by PT UOB Kay Hian Sekuritas, which is regulated by Financial Services Authority of Indonesia ("OJK"). Where the report is distributed in Indonesia and contains research analyses or reports from a foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report.
Malaysia	Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia, at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the registered person under CMSA to distribute any research analyses in Malaysia.
Singapore	This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. Where the report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Thailand	This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated by the Securities and Exchange Commission of Thailand.
United Kingdom	This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in the UK is intended only for institutional clients.
United States of America ('U.S.')	This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S. laws and regulations. It is being distributed in the U.S. by UOB Kay Hian (US) Inc, which accepts responsibility for its contents. Any U.S. person or entity receiving this report and wishing to effect transactions in any securities referred to in the report should contact UOB Kay Hian (US) Inc. directly.

Copyright 2023, UOB Kay Hian Pte Ltd. All rights reserved.

<http://research.uobkayhian.com>

RCB Regn. No. 197000447W